Log in to search using one of your social media accounts:

 

Deep sea creatures provide a guiding light in the quest to develop cancer therapies

(University of Southern California - Health Sciences) Scientists at the Keck School of Medicine of USC use enzymes responsible for marine animal bioluminescence to help researchers test whether cancer immunotherapies work.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

I'm interested in pursuing Radiation Oncology, and was hoping to hear some thoughts on what the future will be like for Radiation Oncologists with some of the advancements in cancer therapy coming out (immunotherapy, for example). From my naive perspective, it seems like the future is pretty uncertain.
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Source Type: forums
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
FINDINGSMelanoma, a relatively rare but deadly skin cancer, has been shown to switch differentiation states — that is, to regress to an earlier stage of development — which can lead it to become resistant to treatment. Now, UCLA researchers have found that melanomas can be divided into four distinct subtypes according to their stages of differentiation. Cell subtypes that de-differentiated — meaning that they reverted back to a less-mature cell — showed sensitivity to a type of self-inflicted cell death called ferroptosis.The research also showed that certain subtypes of melanoma cells could be succ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Publication date: 9 April 2018 Source:Cancer Cell, Volume 33, Issue 4 Author(s): Vancheswaran Gopalakrishnan, Beth A. Helmink, Christine N. Spencer, Alexandre Reuben, Jennifer A. Wargo The microbiome is receiving significant attention given its influence on a host of human diseases including cancer. Its role in response to cancer treatment is becoming increasingly apparent, with evidence suggesting that modulating the gut microbiome may affect responses to numerous forms of cancer therapy. A working knowledge of the microbiome is vital as we move forward in this age of precision medicine, and an understanding of the micro...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
Abstract Immune checkpoint blockade by anti-PD-L1 monoclonal antibody (PD-L1) has achieved unprecedented clinical benefits in certain cancers, whereas the therapeutic efficacy is often hindered by immunosuppressive tumor microenvironment mediated by tumor-associated macrophages (TAMs), which leads to innate resistance to this approach. In order to improve checkpoint blockade efficacy, the amphiphilic diblock copolymers poly(mannopyranoside/galactopyranoside methacrylate)-block-polystyrene were prepared by RAFT polymerization, which were sequentially self-assembled into glycocalyx-mimicking nanoparticles (GNPs) ...
Source: Biomacromolecules - Category: Biochemistry Authors: Tags: Biomacromolecules Source Type: research
AbstractPurpose of ReviewThe landscape of lung cancer therapy has completely shifted in the last decade. From the surge of targeted therapy to the resurrection of immunotherapy, the need for adequate lung tissue specimen is critical to evaluate tumor specimens for predictive biomarkers for both types of therapies, hence, the importance of obtaining several samples via endoscopic bronchial ultrasound performed by pulmonologists or thoracic surgeons. Moreover, these novel therapies have also been associated with respiratory side effects which will require prompt evaluation and aggressive management by pulmonologists, oncolog...
Source: Current Respiratory Care Reports - Category: Respiratory Medicine Source Type: research
Lung cancer is the second most common cancer and the leading cause of cancer-related deaths. Different targeted therapies and the introduction of immunotherapy have successfully improved outcome for patients with non-small lung cancer (NSCLC). Anti-angiogenic drugs are an essential component in the treatment of NSCLC patients. The vascular endothelial growth factor (VEGF)-A antibody bevacizumab is approved for first-line treatment of advanced-stage patients in combination with platinum-based chemotherapy. Ramucirumab, a VEGF receptor antibody, and nintedanib, an anti-angiogenic multi-tyrosine kinase inhibitor, are approved...
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research
Incyte Corp. ’s stock price plunged nearly 20 percent Friday after the Wilmington biotechnology company announced disappointing late-stage study results for an experimental cancer therapy. The results from a phase-III clinical study, testing Incyte’s new drug candidate epacadostat with Merck&Co. Inc. ’s immunotherapy drug Keytruda, found the combination therapy did not improve progression-free survival in patients with metastatic melanoma, a type of skin cancer. Incyte and Merck said, at…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news
Abstract As a treatment for solid tumors, dendritic cell (DC)-based immunotherapy has not been as effective as expected. Here, we review the reasons underlying the limitations of DC-based immunotherapy for solid tumors and ask what can be done to improve immune cell-based cancer therapies. Several reports show that, rather than a lack of immune induction, the limited efficacy of DC-based immunotherapy in cases of renal cell carcinoma (RCC) likely results from inhibition of immune responses by tumor-secreted TGF-β and an increase in the number of regulatory T (Treg) cells in and around the solid tumor. Indeed,...
Source: Translational Oncology - Category: Cancer & Oncology Authors: Tags: Transl Oncol Source Type: research
Routy B, Le Chatelier E, Derosa L, et  al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2017 Nov 2. pii: eaan3706. https://doi.org/10.1126/science.aan3706.
Source: Gastroenterology - Category: Gastroenterology Authors: Tags: Selected Summaries Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Immunotherapy